BiotechTube
Home/Incannex Healthcare/Joel Latham
JL

Joel Latham

Chief Executive Officer & Managing Director

Incannex Healthcare

Therapeutic Areas

Sleep DisordersPsychiatryNeurologyInflammatory Diseases

Incannex Healthcare Pipeline

DrugIndicationPhase
IHL-42XObstructive Sleep ApneaPhase 2/3
Psilocybin-assisted TherapyGeneralized Anxiety DisorderPhase 2b
IHL-675AInflammatory Conditions (Rheumatoid Arthritis/Lung Inflammation)Preclinical
CBD-based formulationTraumatic Brain Injury/ConcussionPreclinical
IHL-216ANeuroprotectionPreclinical

Leadership Team at Incannex Healthcare

SB
Stephen Bond
Chief Financial Officer
DM
Dr. Mark Bleackley
Chief Scientific Officer
DJ
Dr. Julian Kenyon
Medical Director (UK)
PW
Peter Wills AC
Non-Executive Chairman
T(
Terence (Terry) O'Brien
Non-Executive Director
PH
Paul Hopper
Non-Executive Director
PL
Professor Leon Lack
Scientific Advisory Board Member - Sleep Psychology
PD
Professor Danny Eckert
Scientific Advisory Board Member - Sleep Physiology and OSA
DP
Dr. Paul Liknaitzky
Scientific Advisory Board Member - Psychedelic Research Lead
View full Incannex Healthcare profile